Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2- Early Breast Cancer Patients

被引:4
|
作者
Li, Shuai [1 ]
Chen, Xiaosong [1 ]
Shen, Kunwei [1 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Comprehens Breast Hlth Ctr, Dept Gen Surg,Sch Med, Shanghai, Peoples R China
来源
FRONTIERS IN SURGERY | 2022年 / 9卷
基金
中国国家自然科学基金;
关键词
breast neoplasms; core needle biopsy; surgical sample; Ki-67; change; prognosis; INTERNATIONAL EXPERT CONSENSUS; HER2; STATUS; SURGICAL SPECIMENS; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; AMERICAN SOCIETY; KI67; EXPRESSION; WOMEN; INDEX; EXCISION;
D O I
10.3389/fsurg.2022.905575
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background; To investigate the association of Ki-67 change pattern after core needle biopsy (CNB) and prognosis in HR+/HER2- early breast cancer patients. Method: Eligible patients were categorized into three groups: Low group, Elevation group, and High group. Chi-square test and logistic regression analysis were used to compare the clinic-pathological characteristics. Kaplan-Meier method was used to estimate the rates of recurrence-free interval (RFI) and breast cancer-specific survival (BCSS), which were compared via the Log-rank test. Cox proportional hazard analysis was performed to investigate independent prognostic factors. Results: A total of 2,858 patients were included: 1,179 (41.3%), 482 (16.9%), and 1,197 (41.8%) patients were classified into the low, elevation, and high groups, respectively. Age, tumor size, histological grade, lymph-vascular invasion (LVI), and ER level status were associated with Ki-67 change pattern after CNB. With a median follow-up of 53.6 months, the estimated 5-year RFI rates for the low group, elevation, and high groups were 96.4%, 95.3% and 90.9%, respectively (P < 0.001). And 5-year BCSS rates were 99.3%, 98.3% and 96.8%, respectively (P = 0.001). Compared with patients in the low group, patients in the high group had significantly worse RFI (hazard ratio [HR] 1.71, 95% confidence interval [CI] 1.16-2.54) in multivariate analysis. Conclusions: Ki-67 change after CNB was associated with prognosis in HR+/HER2- early breast cancer. Patients with Ki-67 high or elevation after CNB had an inferior disease outcome, indicating the necessity of re-evaluating Ki-67 on surgical specimens after CNB.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Clinicopathological and molecular features of HR+/HER2- breast cancer patients with distinct endocrine resistance patterns
    Zhang, Siwei
    Wang, Han
    Zhang, Hang
    Zhuang, Qingyuan
    Zhu, Xiaohui
    Xiao, Yi
    Jiang, Yizhou
    CHINESE JOURNAL OF CANCER RESEARCH, 2025, 37 (01)
  • [22] Concordance between core needle biopsy and surgical excision specimens for Ki-67 in breast cancer - a systematic review of the literature
    Kalvala, Jahnavi
    Parks, Ruth M.
    Green, Andrew R.
    Cheung, Kwok-Leung
    HISTOPATHOLOGY, 2022, 80 (03) : 468 - 484
  • [23] Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
    Jiaxin, Chen
    Jinmei, Zhou
    Huiqiang, Zhang
    Xuexue, Wu
    Xiaobo, Wang
    Shaohua, Zhang
    Yanhong, Tai
    Zefei, Jiang
    Tao, Wang
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [24] Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer
    Curigliano, Giuseppe
    Dent, Rebecca
    Llombart-Cussac, Antonio
    Pegram, Mark
    Pusztai, Lajos
    Turner, Nicholas
    Viale, Giuseppe
    NPJ BREAST CANCER, 2023, 9 (01)
  • [25] The correlation between Ki 67 and Oncotype Dx on HR+, HER2-early breast cancer management: Insights of molecular testing.
    Campoverde, Leticia
    Camacho, Felipe
    Sanchez, Adriana
    Lugo, Paulina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Effect of HER2 expression status on the prognosis of patients with HR+/HER2- advanced breast cancer undergoing advanced first-line endocrine therapy
    Wang, Kan
    Du, Qinglei
    Yu, Jie
    Li, Yao
    Zhu, Xulong
    ONCOLOGY LETTERS, 2023, 26 (01)
  • [27] The MonarchE trial: improving the clinical outcome in HR+/HER2- early breast cancer: recent results and next steps
    Bertucci, Francois
    Finetti, Pascal
    Mamessier, Emilie
    De Nonneville, Alexandre
    CANCER COMMUNICATIONS, 2023, 43 (08) : 938 - 942
  • [28] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Piudo, Natalia Chavarria
    Blancas, Isabel
    Flores, Encarna Gonzalez
    Carrasco, Fernando Henao
    Alvarez, Pilar Lopez
    Pancorbo, David Morales
    Casado, Salvador Gamez
    Garrido, Maria de la Cabeza Lomas
    Garcia, Jose Manuel Rodriguez
    Guisado, Antonia Martinez
    Vega, Adrian Sanchez
    Borrego, Manuel Ruiz
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (12): : 3131 - 3141
  • [29] ESTIMATIVE OF THE TOTAL NUMBER OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER HR+/HER2-, STRATIFIED BY TREATMENT LINES IN BRAZIL
    Alexandre, R. F.
    Salgado De Santana, C. F.
    Senna, T.
    VALUE IN HEALTH, 2019, 22 : S85 - S85
  • [30] Retrospective registry of patients with locally advanced/metastatic HR+/HER2- breast cancer treated in clinical practice in Andalusia
    Chavarria Piudo, Natalia
    Blancas, Isabel
    Gonzalez Flores, Encarnacion
    Henao Carrasco, Fernando
    Lopez Alvarez, Pilar
    Morales Pancorbo, David
    Baena-Canada, Jose Manuel
    Lomas Garrido, Maria de la Cabeza
    Rodriguez, Jose Manuel
    Martinez Guisado, Antonia
    Sanchez Vega, Adrian
    Ruiz-Borrego, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)